BATON ROUGE, La. (March 16, 2021)—Amedisys, Inc., a provider of home health, hospice and personal care, has repurchased approximately $73 million in stock beginning Monday, March 1. Late in 2020, the Amedisys Board of Directors authorized up to $100 million in share repurchases through Dec. 31, 2021.
“This was a very advantageous time to buy back the stock,” said Paul Kusserow, Amedisys chairman and CEO. “Our shareholders got a great deal on this repurchase. Given our low leverage and very strong cash flow, this repurchase has no impact on our ability to execute upon our inorganic growth strategy and will not impact our plan to deploy capital into acquisitions. Our pipeline in both home health and hospice remains very full and we look forward to getting a few of these deals across the finish line.”
Amedisys, Inc. is a health care at home company delivering personalized home health, hospice and personal care. Amedisys is focused on delivering the care that is best for patients, whether that is home-based personal care; recovery and rehabilitation after an operation or injury; care focused on empowering them to manage a chronic disease; or hospice care at the end of life. Founded in 1982, headquartered in Baton Rouge, Louisiana, with an executive office in Nashville, Tennessee, Amedisys is a publicly held company. With ~21,000 employees, in 514 care centers in 39 states and the District of Columbia, Amedisys is dedicated to delivering the highest quality of care to the doorsteps of more than 418,000 patients in need every year. For more information, visit amedisys.com.
